Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.67 |
| ▸ | CA2 | P00918 | 3/20 | 0.67 |
| ▸ | CES2 | O00748 | 1/20 | 0.67 |
| ▸ | CES1 | P23141 | 1/20 | 0.67 |
| ▸ | ACHE | P22303 | 2/20 | 0.62 |
| ▸ | BCHE | P06276 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18214676 | 0.93 | CA1 (0.59) | CA1CA2CES2CES1ACHE | |
| SCHEMBL25931268 | 0.91 | ALDH1A1 (0.65) | CA1CA2CES2CES1ACHE | |
| SCHEMBL3932149 | 0.88 | CA1 (0.67) | CA1CA2CES2CES1ACHE | |
| SCHEMBL1898027 | 0.86 | CA1 (0.56) | CA1CA2CES2CES1ACHE | |
| SCHEMBL2596732 | 0.86 | CA1 (0.74) | CA1CA2CES2CES1ACHE | |
| SCHEMBL9316829 | 0.85 | CES2 (0.68) | CA1CA2CES2CES1ACHE | |
| SCHEMBL1363815 | 0.85 | CA1 (0.73) | CA1CA2CES2CES1ACHE | |
| SCHEMBL15086926 | 0.84 | CA1 (0.61) | CA1CA2CES2CES1ACHE | |
| SCHEMBL35319 | 0.83 | CA1 (0.71) | CA1CA2CES2CES1ACHE | |
| SCHEMBL14095660 | 0.82 | ALDH1A1 (0.69) | CA1CA2CES2CES1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200109297-A1 | ENZYMATIC ANTIMICROBIAL AND ANTIFOULING COATINGS AND POLYMERIC MATERIALS | REACTIVE SURFACES, LTD., LLP (US) | 2020-04-09 | — | — | US | disclosed |
| US-10413769-B2 | Paint having cell wall particulate material with a protective organophosphorus esterase | REACTIVE SURFACES, LTD., LLP (US) | 2019-09-17 | — | — | US | disclosed |
| US-20170197996-A1 | Cholinesterase Inhibitors | THE UNIVERSITY OF MONTANA (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170197996-A1 | Cholinesterase Inhibitors | THE UNIVERSITY OF MONTANA (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170197996-A1 | Cholinesterase Inhibitors | THE UNIVERSITY OF MONTANA (US) | 2017-07-13 | — | — | US | disclosed |
| CN-101918369-B | Uracil or thymine derivatives for the treatment of hepatitis C | ABBVIE INC. (BS) | 2016-02-24 | — | — | CN | disclosed |
| CN-102746239-B | Uracil or thymine derivatives for the treatment of hepatitis C | ABBVIE INC. (BS) | 2016-02-10 | — | — | CN | disclosed |
| CN-105294569-A | Uracil or thymine derivatives for the treatment of hepatitis C | ABBVIE INC | 2016-02-03 | — | — | CN | disclosed |
| US-20150328490-A1 | BIOLOGICAL ACTIVE COATING COMPONENTS, COATINGS, AND COATED SURFACES | REACTIVE SURFACES, LTD., LLP | 2015-11-19 | — | — | US | disclosed |
| CN-101801935-B | Uracil or thymine derivatives for the treatment of hepatitis C | ABBOTT LAB | 2014-12-03 | — | — | CN | disclosed |
| US-20030078203-A1 | Covalently reactive transition state analogs and methods of use thereof | PAUL, SUDHIR, DR. | 2003-04-24 | — | — | US | disclosed |
| WO-2002079223-A9 | COVALENTLY REACTIVE TRANSITION STATE ANALOGS AND METHODS OF USE THEREOF | UNIV TEXAS (US) | 2003-01-09 | — | — | WO | disclosed |
| WO-2002079223-A2 | COVALENTLY REACTIVE TRANSITION STATE ANALOGS AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-10-10 | — | — | WO | disclosed |
| US-5807688-A | ANTIBODY DIRECTED ANZYME PRODRUG THERAPY | ZENECA LIMITED (GB) | 1998-09-15 | — | — | US | disclosed |
| WO-1996041173-A1 | NANOPARTICLES IMPRINTED WITH RECOGNITION SITES FOR TARGET MOLECULES | MARTINEX R & D INC. (CA) | 1996-12-19 | — | — | WO | disclosed |
| EP-0745673-A2 | Catalytic antibody regulated prodrug therapy | ZENECA LIMITED (GB) | 1996-12-04 | — | — | EP | disclosed |
| US-5314815-A | Method for temporarily inhibiting or deactivating serine hydrolase and adduct of serine hydrolase with a phosphonate or phosphate compound | THE CATHOLIC UNIVERSITY OF AMERICA (US) | 1994-05-24 | — | — | US | disclosed |
| US-5281523-A | Adduct of serine hydrolase and nitrophenyl pnenacyl phosphonate | THE CATHOLIC UNIVERSITY OF AMERICA (US) | 1994-01-25 | — | — | US | disclosed |
| US-5110833-A | Preparation of synthetic enzymes and synthetic antibodies and use of the thus prepared enzymes and antibodies | MOSBACH KLAUS (SE) | 1992-05-05 | — | — | US | disclosed |
| US-4041111-A | PHOSPHONIC ACID DICHLORIDE REACTED WITH 2-NAPHTHOL OR 4-NITRO-PHENOL, HYDROLYSIS | PURDUE RESEARCH FOUNDATION (US) | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197996-A1 | Cholinesterase Inhibitors | BCHE, ACHE, BACE1 | CA1 418/4885CA2 2259/4885CES2 264/4885 |
| US-20030078203-A1 | Covalently reactive transition state analogs and methods of use thereof | SPR, FCGR3B, CD2 | CA1 359/4885CA2 1654/4885CES2 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.